Analysts expect that HCA Healthcare Inc (NYSE:HCA) will post sales of $13.31 billion for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for HCA Healthcare’s earnings, with the lowest sales estimate coming in at $13.08 billion and the highest estimate coming in at $13.47 billion. HCA Healthcare posted sales of $12.27 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 8.5%. The business is scheduled to report its next earnings report on Tuesday, February 4th.
On average, analysts expect that HCA Healthcare will report full year sales of $51.13 billion for the current year, with estimates ranging from $50.89 billion to $51.28 billion. For the next financial year, analysts forecast that the firm will post sales of $53.70 billion, with estimates ranging from $52.89 billion to $54.03 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow HCA Healthcare.
HCA Healthcare (NYSE:HCA) last announced its earnings results on Tuesday, October 29th. The company reported $2.23 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.10. HCA Healthcare had a net margin of 6.98% and a negative return on equity of 173.49%. The business had revenue of $12.69 billion during the quarter, compared to the consensus estimate of $12.48 billion. During the same quarter last year, the firm earned $2.16 earnings per share. HCA Healthcare’s quarterly revenue was up 10.9% on a year-over-year basis.
HCA has been the topic of several research analyst reports. ValuEngine upgraded HCA Healthcare from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America upgraded HCA Healthcare from a “neutral” rating to a “buy” rating in a report on Friday. Finally, Barclays boosted their price target on HCA Healthcare from $145.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $155.69.
Shares of NYSE:HCA traded down $1.77 during midday trading on Friday, reaching $142.84. The company’s stock had a trading volume of 2,438,498 shares, compared to its average volume of 1,642,394. HCA Healthcare has a fifty-two week low of $110.31 and a fifty-two week high of $146.96. The firm has a 50 day moving average price of $135.76 and a two-hundred day moving average price of $129.63. The firm has a market capitalization of $49.05 billion, a price-to-earnings ratio of 14.62, a PEG ratio of 1.22 and a beta of 0.91.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Stockholders of record on Monday, December 2nd will be issued a dividend of $0.40 per share. The ex-dividend date is Friday, November 29th. This represents a $1.60 annualized dividend and a dividend yield of 1.12%. HCA Healthcare’s dividend payout ratio is currently 16.38%.
In other news, SVP Christopher F. Wyatt sold 3,900 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $134.74, for a total transaction of $525,486.00. Following the completion of the sale, the senior vice president now owns 27,353 shares in the company, valued at $3,685,543.22. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jon M. Foster sold 19,477 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of $132.35, for a total value of $2,577,780.95. Following the sale, the insider now owns 10,015 shares of the company’s stock, valued at approximately $1,325,485.25. The disclosure for this sale can be found here. Insiders have sold a total of 40,571 shares of company stock worth $5,431,851 in the last three months. Insiders own 2.70% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in HCA Healthcare by 0.4% during the second quarter. Vanguard Group Inc. now owns 20,865,021 shares of the company’s stock worth $2,820,324,000 after buying an additional 88,231 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of HCA Healthcare by 9.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,906,139 shares of the company’s stock worth $2,150,033,000 after acquiring an additional 1,375,021 shares during the last quarter. Magellan Asset Management Ltd raised its holdings in shares of HCA Healthcare by 21.0% in the 2nd quarter. Magellan Asset Management Ltd now owns 15,621,068 shares of the company’s stock worth $2,111,500,000 after acquiring an additional 2,712,130 shares during the last quarter. Longview Partners Guernsey LTD lifted its position in HCA Healthcare by 9.4% in the 2nd quarter. Longview Partners Guernsey LTD now owns 9,487,250 shares of the company’s stock valued at $1,282,392,000 after acquiring an additional 813,474 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in HCA Healthcare by 1,105.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 3,165,181 shares of the company’s stock valued at $427,837,000 after purchasing an additional 2,902,715 shares during the last quarter. Institutional investors own 69.41% of the company’s stock.
HCA Healthcare Company Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.